Phase A — Understand the business
Lens 1 · Company Overview
Corteva is the only pure-play, scaled, vertically-integrated agricultural-inputs company in the world — it sells both the seed and the chemistry that protects it, to the same farmer, through the same channel. It was carved out of DowDuPont in the 2019 three-way split (the ag piece; Dow took materials, DuPont kept specialty chem) and carries the genetics of two storied franchises: Pioneer (corn/soybean germplasm, founded 1926) and Dow AgroSciences (crop chemistry).
Two reported segments:
- Seed — FY2025 net sales $9.9B (+4%), Operating EBITDA $2.6B (+19%), 26.6% margin. Advanced germplasm + trait technologies (herbicide tolerance, insect/disease resistance) under Pioneer and Brevant. The crown jewel is the Enlist E3 soybean / Enlist corn trait system (2,4-D choline + glyphosate + glufosinate tolerance) — Enlist E3 now commands the dominant share of US soybean acres. ~56% of total sales.
- Crop Protection — FY2025 net sales $7.5B (+2%, +3% organic), Operating EBITDA $1.35B (+6%), 18.0% margin. Herbicides, insecticides, fungicides, plus a fast-growing biologicals book (built via the ~$1.2B Symborg + Stoller acquisitions, 2022–23).
Business model nuance — the royalty engine. Beyond product sales, Corteva runs a trait out-licensing business that is structurally inflecting. Five years ago it was a net royalty payer of ~$700M/yr (mostly to Bayer for stacked traits); it reaches royalty neutrality in 2026 and targets a $1B net royalty income position by 2035 as it becomes a net out-licensor of Enlist.
Contract structure: seasonal, weather- and commodity-price-sensitive, with a heavy Northern-Hemisphere first-half / Brazil-safrinha cadence — not recurring/subscription. Pricing power is real in seed (genetics differentiation) and thinner in crop protection (generic competition, esp. from off-patent actives sourced from China).
THE headline event: On October 1, 2025, the board unanimously approved a tax-free separation into two public companies — "New Corteva" (the Crop Protection business, ~$7.8B sales) and "SpinCo" (the Seed business, ~$9.9B sales), targeted for 2H 2026. CEO Chuck Magro moves to run SpinCo (Seed); Chair Greg Page chairs New Corteva.
Lens 2 · Supply Chain
Map: upstream inputs → Corteva → channel → farmer.
- Upstream — germplasm (Seed): largely proprietary and self-supplied; Corteva owns one of the deepest corn/soy germplasm libraries on earth (Pioneer heritage). This is the part of the chain with no external chokepoint — the moat lives here.
- Upstream — active ingredients (Crop Protection): a real dependency. China is the world's largest supplier of technical-grade actives — glyphosate, atrazine, 2,4-D ester, glufosinate. US tariffs on Chinese AIs are a live cost/availability risk. Industry response — including Corteva's — is dual-sourcing and regionalization into Brazil, India, and US domestic manufacturing to de-risk China concentration.
- Manufacturing: global formulation/seed-production footprint across the Americas, EMEA, Asia. Seed production is itself weather-exposed (you grow the seed you sell).
- Channel — distributors/retail: US ag-retail (independents + co-ops), plus Corteva's own demand-generation. Named channel-adjacent stakeholders: Forestry Distributing (specialty/vegetation-management distribution) is one visible NA distributor.
- End customer: the row-crop farmer (corn, soy, cotton, cereals), concentrated in the US Corn Belt, Brazil (summer + safrinha), Argentina, EU.
Named competitors along the chem chain: Bayer (Crop Science), Syngenta Group (owned by ChemChina/Sinochem), BASF, FMC, UPL.
Chokepoints: (1) Chinese AI supply for crop protection; (2) Brazilian Real / FX as a recurring margin swing; (3) channel-inventory destocking cycles (the 2023–24 crop-protection destocking was the single biggest recent earnings drag). The Seed side is the insulated part of the chain — which is exactly why the split puts Seed in the cleaner vehicle.
Lens 3 · Competitive Advantages (moats)
Moat verdict: wide, and asymmetric across the two segments. Morningstar carries CTVA with a wide-moat rating.
- Seed = the durable moat. Corteva + Bayer together control ~70%+ of the US corn and soybean seed market (one cited figure: 71.6% of US corn, 65.9% of US soybean, 2018–20). Globally Corteva holds ~19% of the seed market. The moat is germplasm + trait IP + regulatory data packages + switching costs (a farmer's agronomy is built around a genetics platform; trait approvals take years and hundreds of millions). Enlist's rise from challenger to category-defining soybean trait is the proof the R&D engine compounds.
- Crop Protection = a narrower, erodible moat. Corteva holds ~10% of the global agrochemical market (vs BASF ~11%, FMC ~6%). Patented actives (e.g. spinosyns, the Rinskor/Arylex chemistries) carry pricing power; once off-patent, Chinese generics compress it fast. Biologicals (targeted to be ~25% of the crop-protection market by 2035) are the growth/defense vector.
- Bargaining power: strong over farmers in branded seed (genetics they want), weak-to-neutral over Chinese AI suppliers, contested in commodity crop protection where the buyer (distributor) has alternatives.
- R&D intensity ~7–8% of sales sustains the trait/active pipeline — the cost of keeping the moat wet.
The most important moat fact for the thesis: the royalty position flip. Going from a ~$700M/yr net royalty payer to neutral (2026) to a targeted $1B net out-licensor (2035) is a structural margin tailwind that is internally generated — it doesn't need crop prices to cooperate.
Lens 4 · Segments
By segment (FY2025):
| Segment | Net sales | YoY | Op. EBITDA | YoY | Margin |
|---|
| Seed | $9.9B | +4% | $2.6B | +19% | 26.6% |
| Crop Protection | $7.5B | +2% (+3% org) | $1.35B | +6% | 18.0% |
| Total | $17.4B | +3% (+4% org) | $3.85B | +14% | ~22% |
Trend & cause: Seed is the margin-expansion story — +19% EBITDA on +4% sales = operating leverage + the royalty tailwind + price/mix in corn. Crop Protection is the recovery story — coming off the brutal 2023–24 channel destocking, +6% EBITDA in 2025 signals the destock is largely behind it, though Latin-American competitive pricing (−10% price in Q3'24, −2% in Q1'26) is still a live drag.
By geography (FY2024, the last full clean year):
| Region | Net sales | % of total |
|---|
| North America | $8,660M | ~51% |
| Latin America | $3,776M | ~22% |
| EMEA | $3,124M | ~18% |
| Asia Pacific | $1,348M | ~8% |
North America (Corn Belt) is the profit engine; Latin America/Brazil is the swing factor — both the growth upside (safrinha corn area, Argentina recovery) and the volatility source (FX, destocking, generic crop-protection pricing). Q1 2026 already showed the recovery thesis working: net sales $4.91B, +11.1% YoY, organic +7%, Op. EBITDA +21%.
Phase B — Measure performance
Lens 5 · Earnings Result
Latest full print — FY2025 (reported Feb 3, 2026):
- Net sales $17.4B, +3% (+4% organic), gains in all regions.
- Operating EBITDA $3.85B, +14% — margin expansion is the headline.
- Operating EPS $3.34, +30%. GAAP income from continuing ops $1.20B; GAAP EPS $1.75. (The GAAP/operating gap is large — see Lens 10.)
- FCF $1.7B, +40%; operating cash flow $2.3B, +27%. Cash conversion materially improved.
- Capital return: $1.5B (≈$1B buyback + dividend raised 6%).
Q4 2025 specifically: EPS $0.22, in line; revenue $3.91B vs ~$4.24B expected — a ~7.8% miss. Stock dipped ~1.85% pre-market to ~$73.65 on the revenue miss against an otherwise strong full-year.
Most recent quarter — Q1 2026: net sales $4.91B, +11.1% YoY, organic +7%, Op. EBITDA +21%, price −2% (LatAm competition). A clear beat and an acceleration, and management reaffirmed the year.
Read: the full-year signal (record EBITDA, +30% operating EPS, 40% FCF jump) is unambiguously strong and quality-of-earnings-positive on the cash line. The quarterly signal is noisier — a Q4 revenue miss on volume/FX timing, then a strong Q1 rebound. The destocking trough is in the rear-view; the royalty flip and price/mix in seed are carrying margins.
Lens 6 · Earnings Calls (sentiment trend)
No transcripts in the research layer; synthesized from press releases + call coverage.
Tone arc, last ~3 years:
- 2023: defensive. Brazil destocking, just-in-time farmer purchasing, generic-import pricing pressure, tighter farmer margins. Management in damage-control on crop protection.
- 2024: stabilizing. Seed strength + "operational execution" offsetting residual crop-protection destocking; began emphasizing cost/productivity and controllables.
- 2025 → 2026: confident and strategic. The vocabulary shifted to "freedom to operate," "royalty neutrality," "out-licensing," "margin expansion," "value creation," and post-October, "two market leaders."
Things they stopped saying: the heavy "destocking / channel-inventory normalization" language that dominated 2023–24 has faded — itself a positive tell. Recurring new phrases: royalty neutrality (2026), accelerated freedom to operate, the $1B licensing decade-upside, separation into two leaders. The narrative pivot is the signal: from "managing a cyclical trough" to "structurally re-rating the business and splitting it to surface value."
Lens 7 · Comps
Pure global peers are scarce — that's the point of a pure-play. Multiples are `` with source/date or marked not-sourced. Never fabricated.
| Company | Ticker | Mkt cap (USD) | EV/EBITDA | P/E (fwd) | Div yield | 5yr avg ROE |
|---|
| Corteva | CTVA | ~$57–58B | 13.0x | 20.5x fwd (29.8x ttm) | ~1.0% | n/a |
| FMC | FMC | n/a | ~9x | n/a | n/a | n/a |
| Bayer | BAYRY/BAYN | n/a | n/a | n/a | n/a | n/a |
| Nutrien | NTR | n/a | n/a | n/a | n/a | n/a |
| Mosaic | MOS | n/a | n/a | ~170x ttm (depressed earnings) | n/a | n/a |
| CF Industries | CF | n/a | n/a | ~10x ttm | n/a | n/a |
What the table says: Corteva trades at a clear premium to pure crop-protection (FMC ~9x vs CTVA ~13x EV/EBITDA) — the market is paying up for the integrated seed-led model and the royalty inflection. Fertilizer names (MOS/CF/NTR) are a different business (commodity nutrients, not genetics/chemistry) and are poor multiple comps despite sharing the "ag" label. The cleanest read-through: post-split, SpinCo/Seed should command a premium re-rate (genetics moat, royalty income, no legacy liabilities) while New Corteva/Crop-Protection should trade closer to the FMC ~9x band plus a liability discount. Sum-of-the-parts is the entire bull case for the separation.
Provenance flag: I could not source clean, current EV/EBITDA, ROE, or dividend yields for Bayer/Nutrien/most peers without primary data. Those cells are honestly marked n/a rather than filled with plausible fabrications. A hybrid re-run would pull these.
Lens 8 · Stock-Price Catalysts
Pattern of >5% moves and what the market actually reacts to:
- 2022: crop-protection pricing power (raw-material pass-through, +7% CP price) — commodity supercycle tailwind moved the stock up.
- 2023 (down): Brazil destocking + generic crop-protection price war — repeated guide-downs; the dominant negative catalyst of the cycle.
- 2024: Seed-led beats vs crop-protection drag — bifurcated reaction; FX (Brazilian Real) repeatedly cited.
- Feb 3, 2026 (mixed/down ~2%): Q4 revenue miss (−7.8%) despite a record full year — the market punished the top-line miss short-term.
- Oct 1, 2025 (down ~9% on the day): the separation announcement initially sank the stock ~9% — analysts disliked that all legacy liabilities (PFAS, pension, chlorpyrifos) stay with New Corteva rather than being split, raising "why now / who's holding the bag" questions. This is a critical tell: the market's biggest single reaction to the split was about the liability allocation, not the strategic logic.
- Q1 2026 (up): strong beat (+11% sales, +21% EBITDA) re-rated the recovery.
What the market reacts to, ranked: (1) Brazil/LatAm crop-protection pricing & destocking, (2) crop-commodity prices (corn/soy), (3) FX (BRL), (4) corporate-action / liability news (the split), (5) the royalty/licensing narrative. It is a cyclical-input stock with a structural-re-rating option embedded — the catalysts that move it most are still the ag cycle, but the thesis catalysts (royalty flip, split) are what could break it out of the cyclical band.
Phase C — Judge people & books
Lens 9 · Management
- CEO — Chuck (Charles) Magro (since Nov 1, 2021). Track record: strong and directly relevant. Ran Agrium (2014–18), architected the Agrium/PotashCorp merger into Nutrien (2018), then ran Nutrien (2018–April 2021) — 27,000+ employees, "industry-restructuring" M&A, dividend growth + buybacks. He is a capital-allocator and structural-restructurer by background — which makes the Corteva royalty re-rate, the biologicals roll-up, the Bayer settlement, and the 2026 split read as exactly the playbook you'd hire him for. He moves to run SpinCo (Seed) post-split — a tell that management views Seed as the higher-quality growth vehicle.
- Chair — Greg Page (ex-Cargill CEO) becomes Chair of New Corteva. Deep ag pedigree.
- Capital-allocation history at Corteva: disciplined. FY2025 — $1.5B returned ($1B buyback + 6% dividend raise), FCF $1.7B (+40%), biologicals M&A (~$1.2B Symborg+Stoller) that fits the strategy, and the $610M Bayer settlement that buys a ~$1B-decade licensing upside — a high-IRR legal/strategic trade.
- Skin in the game / insider ownership: n/a (DEF 14A on EDGAR would carry it; not fetched). Comp structure detail also not sourced — flagging the gap honestly.
- Archetype: professional manager / portfolio surgeon, not founder. For a mature, cyclical, post-spin conglomerate-of-two, that is the right archetype — the value here is created by structure, capital discipline, and licensing strategy, not founder-visionary product bets.
- Red flags on management: none obvious. The clearest governance question is the separation's liability allocation (Lens 8/10) — whether loading New Corteva with all legacy liabilities while Magro takes the clean Seed-Co is optimal for all shareholders or advantageous to one entity's narrative.
Lens 10 · Forensic Red Flags
Web-only — no financials.csv/filings to tie out; figures from releases/coverage. Treat as screening-grade, not audited.
- GAAP vs operating EPS gap is wide: GAAP EPS $1.75 vs operating EPS $3.34 (FY2025). ~$1.6/sh of add-backs. For a company with this much legacy litigation, restructuring, and amortization of acquired intangibles (Pioneer/Dow/Stoller), a gap is expected — but it's large enough that operating EPS flatters the picture and the GAAP line is what ultimately funds liabilities. Watch the bridge: how much is non-cash amortization vs recurring "one-time" legal/restructuring charges.
- Legacy environmental liabilities — the headline forensic item:
- PFAS: the 2021 DuPont/Corteva/Chemours cost-share covers up to $4B over 20 years (DuPont+Corteva split half, Chemours half). Corteva was part of an August 2025 comprehensive PFAS settlement with US water systems (up to ~$2B reported). These are long-tail, real, and cash-consuming.
- Chlorpyrifos (Lorsban): Corteva (ex-Dow AgroSciences) held the federal registration; faces personal-injury torts alleging neurological harm in children. Stopped selling it Feb 2020; EPA revoked food tolerances Aug 2021. Open litigation tail.
- DuPont pension legacy obligation.
- CRITICAL STRUCTURAL POINT: the separation assigns ALL of these (PFAS, chlorpyrifos, DuPont pension) to New Corteva (Crop Protection) — SpinCo (Seed) is insulated. This is the single most important forensic fact for valuation: Seed-Co is a clean compounder; Crop-Protection-Co is a decent business wearing a litigation backpack.
- Working capital / seasonality: ag-input working capital swings hard with the Brazil season; the 40% FCF improvement in 2025 suggests good discipline, but a single weak Brazil season can reverse it. Watch receivables in LatAm (farmer credit risk).
- Goodwill/intangibles: large from the DowDuPont carve-out + Pioneer + biologicals deals — impairment risk if crop-protection competitive dynamics worsen.
Regulatory findings (required sub-section) — per regulatory/regulatory-findings.md (Stage 1):
- SEC (EDGAR LR + AAER): the pre-fetched file reports 0 SEC findings and notes "Corteva has no CIK" in the research index (a data-layer gap — Corteva does file; CIK 0001755672). No SEC enforcement (LR/AAER) surfaced.
- Non-SEC enforcement (web): the material item is antitrust — in May 2020 the FTC subpoenaed Corteva over crop-protection rebate/loyalty programs and pricing; on Sept 29, 2022 the FTC + 10 state AGs (CA, CO, IL, IN, IA, MN, NE, OR, WI, TX) sued Corteva (and a competitor, Syngenta) alleging unfair methods of competition, unlawful payment-conditioning/loyalty programs, restraint of trade, and unlawful monopoly; TN, WA, and a separate AR AG suit followed (Dec 2022); private class actions were centralized into an MDL in the MD of North Carolina (Feb 2023). Status as of this dossier: ongoing; outcome not sourced. This is a genuine overhang on the crop-protection (New Corteva) side and ties to the rebate-program model itself.
- 10-K Item 3 (Legal Proceedings): n/a — 10-K not in research layer (not fetched per run contract). Would be the authoritative source for all of the above; flagged for a hybrid re-run.
- Net: Material legal/regulatory overhang exists — PFAS/chlorpyrifos environmental + FTC/AG antitrust — but it is disclosed, quantified where possible, and being structurally ring-fenced into New Corteva by the split. No accounting-fraud signal. The risk is liability magnitude and timing, not integrity of the books.
Phase D — Project & stress-test
Lens 11 · Forward Projection
Built bottom-up from FY2025 actuals + company guidance. All outputs ``; inputs labeled. No forecast.ts create (breadth loop).
Anchors: FY2025 operating EPS $3.34; FY2026 company guidance operating EPS $3.45–$3.70 (midpoint ~$3.58, +7%), Op. EBITDA $4.0–4.2B (+7% mid). Consensus 12-mo target $89.38 (Buy; 15/0/7), range $77–$100, from 21 analysts.
| Year | Bear | Base | Bull | Key input logic |
|---|
| FY2026 | $3.40 | $3.58 | $3.72 | Base = guidance midpoint. Bear = LatAm price war deepens / BRL weakness / soft corn. Bull = top of guide + early licensing $ + biologicals. |
| FY2027 | $3.55 | $3.95 | $4.40 | Base — Enlist corn/cotton licensing turns on (post-Bayer, as early as 2027) + continued seed margin expansion + royalty flip fully positive. Bull adds faster licensing ramp. |
| FY2028 | $3.75 | $4.35 | $5.00 | Base — separation complete (2H26); two focused entities with sharper capital allocation; royalty income compounding toward the $1B-by-2035 path; biologicals scaling. Bear = secular crop-protection generic erosion + a Brazil shock. |
Caveat: post-split (2H26), "Corteva EPS" bifurcates into SpinCo (Seed) EPS + New Corteva (Crop Protection) EPS — these projections are pre-split consolidated; the real FY2027–28 exercise is two separate models. The structural point holds: the earnings algorithm is mid-to-high-single-digit organic + a royalty-flip kicker + a one-time SOTP re-rate from the split. Brier forecast to log on a hybrid re-run (not now): "CTVA FY2026 operating EPS ≥ $3.55, p≈0.62."
Lens 12 · Bull vs Bear
Bull case. Corteva is a wide-moat, seed-led duopolist that just engineered three simultaneous value unlocks: (1) the royalty flip from −$700M payer to a targeted +$1B net out-licensor — a self-generated margin tailwind independent of crop prices; (2) the $610M Bayer settlement buying ~$1B of decade licensing upside plus freedom to license triple-stack corn (2027) and enter cotton; (3) the 2H26 tax-free split that lets the market separately re-rate a clean, high-margin (26.6% EBITDA) Seed compounder away from a liability-laden crop-protection business — classic SOTP value surfacing. Layer on the biologicals growth (→25% of crop-protection market by 2035), record FY2025 EBITDA (+14%) and FCF (+40%), and a strong Q1'26 (+21% EBITDA), and you have a business transitioning from "cyclical input supplier" to "genetics-IP + royalty annuity." Multiples (13x EV/EBITDA, 20.5x fwd P/E) are full but defensible for the quality, and the split is the catalyst to crack them higher.
Bear case. Three things that could permanently impair or de-rate: (1) Crop-protection secular generic erosion — ~10% global share in a business where Chinese off-patent actives structurally compress price; New Corteva inherits this plus every legacy liability (PFAS up to ~$2B net, chlorpyrifos torts, DuPont pension, FTC/AG antitrust MDL). (2) Ag is cyclical and FX-whipped — the 2023–24 Brazil destocking torched two years of crop-protection earnings; corn/soy price weakness + a Brazilian Real shock could do it again, and the seed-volume growth leans on Brazil safrinha acreage that is itself weather/price-contingent. (3) The split could disappoint — if the market values the combined entity below the SOTP (dis-synergies, stranded costs, a liability-discounted New Corteva that drags), the re-rate thesis fails; recall the stock fell ~9% on the announcement, largely on the liability-allocation question.
Pre-mortem (18 months out, thesis broke): It's late 2027. The split closed but New Corteva trades at a deep liability discount (a fresh PFAS or chlorpyrifos verdict re-priced the tail), SpinCo's premium re-rate underwhelmed because a soft Brazil season + LatAm price war hit seed volumes, and the royalty/licensing ramp slipped (corn licensing slower than the 2027 hope). The "two market leaders" became "a clean small-cap-ish seed company and an orphaned crop-protection company nobody wants." The combined market cap is below pre-split.
Are multiples too high? Fair-to-fullish. 13x EV/EBITDA / 20.5x fwd P/E is a premium to FMC (~9x) that the seed moat + royalty flip earn — but it prices in the inflection working. There's modest margin of safety, not a lot.
Contrarian view (what the market refuses to see): The consensus frames CTVA as a steady ag-cycle compounder with a corporate-action catalyst. The market is under-weighting the royalty annuity — a −$700M-to-+$1B swing is a $1.7B run-rate pre-tax improvement that is structural, high-margin, and largely crop-price-independent. The Seed-Co that emerges in 2H26 could re-rate not as "ag inputs" but as a genetics-IP + royalty business — a categorically higher multiple. Conversely, the market may be too sanguine on New Corteva — bundling all legacy liabilities into the lower-quality, generic-exposed business is a setup for a value-trap, not a value-unlock, on that side.
Lens 13 · Devil's Advocate (short-seller)
Dismantling the bull case.
- What structurally breaks the model: the crop-protection half is a price-taker in commodity actives — Chinese generics structurally erode the part of the P&L that isn't germplasm. If biologicals don't scale fast enough to offset, New Corteva is a melting ice cube wearing a litigation backpack.
- Revenue concentration: heavy in corn/soy and in North America + Brazil. A multi-year row-crop price downcycle (farmer income squeeze → traded-down seed/chem spend) hits both segments at once. Brazil is both the growth story and the single biggest historical disappointment (2023–24).
- Why the moat is weaker than bulls think: the seed moat shares the duopoly with Bayer — and the same Bayer it just paid $610M to settle with and now plans to license to/compete with. Trait leadership is a treadmill — Enlist's dominance invites the next-gen trait war, and germplasm advantages erode as gene-editing (CRISPR) lowers entry barriers over time.
- Most dangerous underestimated competitor: Bayer Crop Science (still the other half of the duopoly, recovering from its own Roundup litigation and motivated to defend seed share) and, longer-term, Chinese state-backed Syngenta/ChemChina scaling in both seed and chem with a lower cost of capital.
- Worst capital-allocation / governance angle: the separation's liability allocation — parking PFAS + chlorpyrifos + pension + antitrust entirely on New Corteva while the CEO takes the clean Seed-Co. A short would argue this is value-shifting dressed as value-surfacing, and that the combined entity's liabilities don't shrink — they just get a worse home and a forced seller base.
- Assumptions that must hold for today's price: (1) royalty flip delivers ~on schedule; (2) crop-protection destocking stays over and LatAm pricing stabilizes; (3) the split closes tax-free in 2H26 and both pieces re-rate; (4) no large adverse PFAS/chlorpyrifos verdict. Break any one and the premium-to-FMC compresses.
- If growth disappoints 20–30%: operating EPS to ~$2.50–2.80 → on a de-rated ~14–16x that's a $40–45 stock, i.e. ~45%+ downside from ~$83. The cyclicality cuts both ways.
- Single permanent-impairment scenario: a landmark PFAS or chlorpyrifos liability re-estimate that blows past the $4B cost-share envelope, landing on New Corteva — plausibility low-to-moderate but non-trivial given 20-year tails and active tort dockets.
Lens 14 · Management Questions (ordered by information value)
- Post-split, what is the steady-state net royalty income trajectory for SpinCo (Seed), and how much of the path to $1B-by-2035 is contracted vs aspirational?
- Why were all legacy liabilities (PFAS, chlorpyrifos, DuPont pension, FTC/AG antitrust) assigned to New Corteva rather than shared — and what's the after-tax NPV of that liability stack New Corteva will carry?
- What is the realistic timing and dollar ramp of corn (2027) and cotton trait licensing under the Bayer settlement, and what's contracted today?
- In crop protection, what share of the portfolio is patent-protected vs off-patent, and how fast does the patented mix erode over the next five years against Chinese generics?
- How exposed is each post-split entity to a prolonged corn/soy price downcycle, and what's the decremental-margin math?
- What are the expected dis-synergies and stranded costs of the separation, and the one-time cash cost to execute it?
- What is biologicals' current revenue and growth, and the path to the cited ~25%-of-crop-protection-market-by-2035 — organic or more M&A?
- How should we think about SpinCo's capital structure and capital-return policy vs New Corteva's, given the liability split?
- What's the current status and range of outcomes on the FTC + state-AG antitrust MDL, and does it threaten the loyalty/rebate program economics that underpin crop-protection sales?
- How resilient is the Brazil/LatAm business to another destocking/FX cycle — what structurally changed since 2023–24?
- What is insider ownership and how is post-split executive comp aligned to each entity's value creation (esp. yours at SpinCo)?
- How does gene-editing/CRISPR change the seed competitive moat over 5–10 years — tailwind (your platform) or barrier-lowering threat?
- What's the R&D reinvestment rate for each entity post-split, and how do you protect trait leadership against Bayer and a scaling Syngenta?
- What ROIC did the Symborg/Stoller biologicals acquisitions actually generate, and what's the M&A appetite/discipline for each new company?
- What would have to be true for you to not do the split — and what's the contingency if market conditions force a delay past 2H26?